Venture Capital & Startup Funding Roundup, August 11, 2026: Bessemer Venture Partners, Citi, Sequoia Capital, Thiel Capital & More

The big picture from today’s activity: investors are pouring money into industry-specific AI and hardware-infused sectors. We see a surge of capital into defense and aerospace startups (for example, drone-maker Neros and air-taxi maker Vertical Aerospace) alongside hefty bets on AI-driven life sciences and healthcare (rare-disease biotech Vaderis, AI‑drug-discovery firm Aureka, MSK health platform Flagler). At the same time, infrastructure plays in finance and enterprise are drawing large rounds: inKind’s massive $414M restaurant-fintech facility and Quartr’s AI-powered IR data platform stand out. This mix of deals suggests VCs are favoring “hard-tech” and vertical-AI domains – from national security drones to real-world health systems – more than generic consumer or crypto bets.

Put another way, capital is flowing into startups that tackle real-world problems with tech heft. AI isn’t just hyped here; it’s being baked into domains like insurance (Axle), real estate (ApartmentIQ), and life sciences (Aureka). The largest rounds today, from $250M to $17.5M, all back companies promising tangible, scalable outcomes. In skybound tech, we see Vertical’s €86.6M air‑taxi financing, underscoring continued faith in eVTOL air mobility. On the ground, billions support models that blend data and hardware – from 3D-printed aerospace parts (Stratasys) to autonomous medical devices. Investors are signaling that this is a day for “applied AI” and hardware-enabled innovation. These funding flows suggest a startup market focused on strategic, capital-intensive sectors – where the rewards may be great but so are the hurdles.

Today’s capital movements reflect that pattern: robust funding for companies at the intersection of AI, data, and specialized hardware or science. The prominence of defense, health, and vertical-SaaS rounds indicates where investor confidence lies. The inaugural theme? AI-Powered Industry Sectors and Sovereign Tech – characterized by the fact that big money is heading into critical tech domains (defense drones, biotech AI, energy/infra) rather than games or social apps. VCs appear to be favoring companies that can leverage advanced R&D, capture large industries, or serve public needs. As we detail below, the top rounds of the day illustrate this blend of advanced tech and tangible market focus.

The Macro Environment: Capital Flows to Industrial AI & Defense Tech

Investors are concentrating on startups with deep technology moats. The biggest funding rounds today are not for consumer apps but for sectors requiring advanced R&D or supporting national priorities. Neros’s $250M Series C and Vertical Aerospace’s €86.6M financing commitments are prime examples of hefty bets on aerospace and defense – areas traditionally seen as requiring big capital and with long time horizons. Meanwhile, biotech and healthcare AI are also in vogue: today’s $152M Series B for Vaderis (a Swiss rare-disease drug developer) and $100M Series B for Aureka (an AI-driven drug discovery platform) show that investors still prize life-science innovation. The signals: deeptech meets “applied AI.”

This concentrated capital trend is partly driven by geopolitical and macro factors. With increasing government interest in supply chains and defense, startups like Neros (building a million domestic drones) are attracting strategic funding from both VCs (Sequoia) and public tech funds (ASTF). Healthcare is another focus, as aging populations and post-COVID demand keep interest high. Flagler Health’s new $50M MSK platform raise (led by Bessemer) exemplifies how venture dollars are chasing AI tools for pervasive health problems. In summary, public and private money are coalescing behind sectors viewed as “critical infrastructure” or essential services, pushing valuations up and rounds into the hundreds of millions.

Investor psychology today looks cautious but targeted: large amounts into fewer, “safe” bets. Capital concentration is evident – the top five deals dwarf the rest, and some companies (like inKind) are financing growth without taking equity dilution. The macro backdrop (ongoing inflation, higher interest rates) means ordinary tech startups face tougher scrutiny, so we see less hype-driven funding. Instead, deals suggest a focus on return potential and defensibility. In this climate, founders with real assets (patents, contracts, or “software + hardware” products) are commanding attention. In short, today’s funding scene feels strategic and capital-intensive.

Neros Technologies raises $250M to scale autonomous defense drones

Neros Technologies is a Southern California startup building large fleets of autonomous UAVs for the military and its allies. It closed a $250 million Series C led by Sequoia Capital and the U.S. Defense Department’s American Strategic Technology Fund (ASTF), with participation from Valor Equity Partners, Thiel Capital, Spark Capital and others. The company plans to use this capital to accelerate production of its “Archer AI” strike drone and “Bandit” counter-UAS interceptor.

Investors care because Neros has a rare vertical setup: it owns the entire drone stack (from hardware to AI) and already has major U.S. DoD contracts. CEO Soren Monroe-Anderson emphasizes that this funding is intended to reach “the scale needed for decisive outcomes on the battlefield”, underscoring demand for mass-produced, attritable drones. In the context of recent conflicts, Neros’s ability to promise “one million drones per year by 2028” and a post-money valuation of $2.5 billion has clearly resonated. The scale of this round signals a renewed defense-tech boom: VCs and government coffers alike are pouring resources into sovereignty in robotics.

Funding Details
Startup: Neros Technologies
Investors: Sequoia Capital (lead), ASTF (lead), Interlagos, Valor, Allen & Co, Thiel Capital, Spark Capital, and more
Amount Raised: $250 million (Series C)
Total Raised: $250 million
Funding Stage: Series C
Funding Date: Aug 11, 2026
Headquarters: Torrance, California, USA
Sector: Defense / Autonomous Drones

Vaderis Therapeutics raises $152M in funding to accelerate rare-disease treatments

Vaderis Therapeutics, a Swiss biotech company, announced a $152 million oversubscribed Series B on August 11. The round was led by Goldman Sachs’s life sciences arm, TCGX Life Sciences, and Omega Funds, with participation from Perceptive Advisors, Medicxi, and others. Vaderis uses gene therapy and other advanced modalities to target rare neurological disorders, and the new funding will support its lead program moving into pivotal trials. Investors are pouring money into this company’s lane because rare diseases can command high value, and Vaderis already has clinical data for its neuroscience assets.

The $152M boost, which included a $17.5M slice from GS Life Sciences, reflects confidence in biotech pipelines, especially in platform-stage firms that blend cutting-edge science with regulatory clarity. In today’s market, a mid-size biotech with strong patents can still attract large rounds: Vaderis’s oversubscribed financing and high-profile backers signal that VCs still prize hard-science ventures, even if general tech funding is more selective.

Funding Details
Startup: Vaderis Therapeutics
Investors: Goldman Sachs Life Sciences (lead), TCGX Life Sciences (lead), Omega Funds, Perceptive Advisors, Kalehua Capital, Medicxi, Droia Ventures
Amount Raised: $152 million (Series B)
Total Raised: $152 million
Funding Stage: Series B
Funding Date: Aug 11, 2026
Headquarters: Basel, Switzerland (Swiss biotech)
Sector: Biotechnology / Rare Disease Therapeutics

inKind closes $414M facility led by Citi & Cross River for restaurant financing

In a sizeable fintech play, inKind announced a $414 million financing facility, led by Citi and Cross River Bank, boosting its total capital to over $1.2 billion. inKind is not a consumer app but a B2B restaurant commerce platform: it provides growth capital and marketing to independent restaurants in exchange for revenue share. Its platform ties together upfront funding, guest discovery, loyalty rewards, and proprietary analytics (with an “AI-native” layer). Investors care because inKind is effectively becoming an institutional funding engine for the $900B restaurant sector.

The new tranche includes $175M from Citi and $150M from Cross River, plus mezzanine lenders Sagard, Varadero, Trinity, and Liberty Mutual Investments (which committed $320M earlier). Notably, Citi—a global bank—joined as a senior lender, validating inKind’s model. CEO Johann Moonesinghe explains that this infusion gives “capacity to scale the restaurant commerce infrastructure we have spent more than a decade building”. In practical terms, inKind will deploy over $1B in capital to nearly 10,000 restaurants in the coming year. The sheer size of this facility highlights a trend: VCs and banks are now treating curated restaurant lending as a mature asset class. Founders should note that sectors like hospitality can attract large, structured financing once a startup proves the business model.

Funding Details
Startup: inKind (formerly inKind Capital)
Investors: Citi (lead), Cross River Bank (lead), Sagard, Varadero Capital, Trinity Capital (senior and mezzanine lenders); Liberty Mutual Investments (anchor lender)
Amount Raised: $414 million (capital facility)
Total Raised: $1.2+ billion (including previous debt/equity)
Funding Stage: Growth financing (debt/equity mix)
Funding Date: Aug 11, 2026 (facility closure)
Headquarters: New York, USA (restaurant fintech)
Sector: Fintech / Hospitality Commerce Platform

Aureka Biotechnologies raises $100M in funding for AI-driven drug discovery

Aureka Biotechnologies, a US–China life-science startup, closed a $100 million Series B on August 10. Aureka develops large AI “foundation models” of biology to automate drug design – essentially using deep learning and robotics to “build a biological world model” for discovery. Investors like this approach as the next frontier of biotech: they see high leverage in combining AI models with lab automation. Granite Asia led the first tranche of this round, joined by strategic biopharma investors (names undisclosed), plus existing backers like HighLight Capital.

The new capital will fund massive compute training and lab-automation expansions, aiming to accelerate moves from protein-folding predictions to actual drug candidates. Crucially, Aureka already reported meaningful revenue from partnering with pharma. CEO Weian Zhao notes that combining “foundation models” with live R&D is the future of drug pipelines. This round underlines an industry trend: AI-native biotech is hot again. For startup readers, Aureka’s round shows that blending data science with hard biology can merit VC stakes in nine figures, especially when the platform yields tangible outputs.

Funding Details
Startup: Aureka Biotechnologies
Investors: Granite Asia (lead), undisclosed strategic investors, HighLight Capital, MPCi, NRL Capital, other existing backers
Amount Raised: $100 million (Series B)
Total Raised: ~$200 million to date
Funding Stage: Series B
Funding Date: Aug 10, 2026
Headquarters: Laguna Hills, California, USA (and Shanghai)
Sector: Biotechnology / AI-Driven Drug Discovery

Vertical Aerospace secures $100 million in funding for its electric eVTOL project

UK aerospace startup Vertical Aerospace announced $100 million (~€86.6 million) in financing commitments on August 11. The Bristol‑based company is developing the Valo electric vertical‑takeoff aircraft for short-range passenger air travel. This “financing” is arranged as a mix of debt draws and equity: Mudrick Capital Management is providing a €34.6M note draw, a €35M underwritten equity unit raise, and €21.6M via preferred stock with Yorkville. These near-term commitments fund Vertical’s certification and commercialization push for 2026-27.

The company is already public, and this capital infusion effectively scores as fresh funding for a startup still scaling up. Investors (like Mudrick) are betting that Vertical’s progress (including piloted eVTOL demonstrations at Farnborough) will pay off. As CEO Stuart Simpson notes, the goal is to leverage recent “operational momentum” into finalizing certification steps. For founders, Vertical’s news highlights how “hard” tech ventures (even public ones) can attract multi-ten-million commitments for milestones. For the market, it shows that climate/airmobility (once tapped out) still draws capital when paired with solid tech demos and strategic partners.

Funding Details
Startup: Vertical Aerospace (NYSE: EVTL)
Investors: Mudrick Capital Management (draws and commitments), Yorkville Advisors Global (preferred equity), plus unnamed existing and new investors
Amount Raised: €86.6 million (in financing commitments)
Total Raised: company is publicly traded (market cap ~$?), funds structured via notes and equity draws
Funding Stage: Corporate financing (convertible notes and equity)
Funding Date: Aug 11, 2026
Headquarters: Bristol, United Kingdom
Sector: Aerospace / Electric Vertical Takeoff (eVTOL) Aircraft

Flagler Health raises $50M Series B funding to expand AI healthcare platform

Flagler Health, a New York startup building an AI-powered platform for musculoskeletal (MSK) care, secured $50 million in Series B funding. This brings Flagler’s total raised to $63 million. The round was led by Bessemer Venture Partners, with participation from SignalFire, Alumni Ventures, and other investors. Flagler’s software aggregates patient data, AI models, and care protocols to streamline treatment for joint, spine, and injury care.

Investors view Flagler as a timely solution to the $400+ billion U.S. MSK market, which affects over half of adults. In practice, that means the platform can reduce costs and improve outcomes in orthopedics and rehab by providing predictive analytics and treatment roadmaps. For founders, this round underlines continued investor appetite for health-tech that applies AI to real clinical problems. For the market, it signals that even in a tough funding environment, healthcare startups with clear use cases (and established VC backers) can still raise significant capital.

Funding Details
Startup: Flagler Health
Investors: Bessemer Venture Partners (lead), SignalFire, Alumni Ventures, Streamlined Ventures, 186 Ventures, Proof VC, Tribeca Venture Partners, Offscript (participants)
Amount Raised: $50 million (Series B)
Total Raised: $63 million to date
Funding Stage: Series B
Funding Date: Aug 11, 2026
Headquarters: New York, USA (AI-driven healthcare)
Sector: Healthcare AI / Musculoskeletal Care

ApartmentIQ raises $25 million in follow-on funding to scale property AI

Madison-based ApartmentIQ, which provides a real-time market intelligence and revenue-management platform for multifamily real estate, announced a $25 million growth investment from Susquehanna Growth Equity. SGE had earlier led ApartmentIQ’s $22.5M Series B in 2021 (when the company was known as Rentable). The new capital will fuel continued AI enhancements and customer acquisition in the large U.S. apartment market. ApartmentIQ’s software uses machine learning to adjust rents and predict vacancies, which helps landlords maximize revenue.

Investors are interested because the proptech space (particularly AI-driven pricing tools) has matured; ApartmentIQ claims 8 million “customer units” and strong revenue retention, making it one of the largest players in its niche. In effect, this follow-on validates that enterprise SaaS startups in traditional industries can keep attracting growth capital. For founders, it shows that even industries like real estate – far from Silicon Valley – can build “AI for industry” businesses that raise tens of millions from top funds.

Funding Details
Startup: ApartmentIQ
Investors: Susquehanna Growth Equity (lead; existing investor)
Amount Raised: $25 million (follow-on investment)
Total Raised: ~$47.5 million (including prior $22.5M)
Funding Stage: Growth Equity (Series B extension)
Funding Date: Aug 11, 2026
Headquarters: Madison, Wisconsin, USA
Sector: Real Estate / Property Tech (AI-driven multifamily)

Axle raises $17.5 million in Series A funding to streamline insurance operations

Axle, a startup building an “AI-native clearinghouse for insurance,” closed a $17.5 million Series A led by Base10 Partners. Axle’s platform connects large insurance carriers to payments and backend services via data APIs and AI agents. Investors, including Gradient, Y Combinator, and industry vets, backed Axle because the insurtech sector is ripe for cost reduction and automation.

The company promises to handle invoicing and settlements without manual reconciliation. In practice, Axle’s AI replaces legacy back-office work, making large enterprise insurance contracts easier to execute. For startup watchers, Axle’s round exemplifies how deep technological questions (in this case, complex payments and data issues in finance) are attracting venture funds. It reflects a broader trend: as financial networks digitize, new infrastructure plays (like Axle’s) are emerging.

Funding Details
Startup: Axle
Investors: Base10 Partners (lead), YC, Gradient, Stage 2 Capital, early team from Plaid, angel investors
Amount Raised: $17.5 million (Series A)
Total Raised (including seed) likely ~$22M (not explicitly stated)
Funding Stage: Series A
Funding Date: Aug 11, 2026
Headquarters: New York, USA (insurance fintech)
Sector: Fintech / Insurtech (Enterprise Payments)

Quartr lands €15.6M (18 million) in funding to expand AI-ready finance data platform

Quartr, a Stockholm startup, secured €15.6 million ($18M) in funding (led by Altos Ventures with participation from SEB) on August 11. Quartr is an “AI infrastructure” for investor relations, offering structured, real-time transcripts, filings, and analytics on public companies. Hedge funds and IR teams use its AI-driven platform and API to query company data with citations. Investors are betting that Quartr’s first‑party data layer can become a standard in financial modeling and research.

With triple-digit growth and large clients (800+ institutional users), Quartr’s raise values it as a rapidly scaling enterprise SaaS. This round highlights that “market intelligence” startups can still raise large sums, especially in Europe where dedicated financial data providers are winning capital. For founders, it underscores that B2B AI tools for finance (a form of vertical AI) remain attractive to VCs, even if amounts are smaller than consumer rounds.

Funding Details
Startup: Quartr
Investors: Altos Ventures (lead), SEB (new investor)
Amount Raised: €15.6 million (Series A)
Total Raised: ~€23 million to date (including €7M prior seed)
Funding Stage: Series A
Funding Date: Aug 11, 2026
Headquarters: Stockholm, Sweden
Sector: Fintech / AI-driven Investment Data Platform

Versa Vascular expands Series C by $15 million to advance heart devices

Medtech startup Versa Vascular of Santa Cruz, CA, announced a $15 million expansion to its Series C on August 11. This brings the total Series C round to $42 million. Versa develops a transcatheter implant to repair tricuspid heart valves without open surgery. The fresh capital (an “expansion”) will support clinical trials of Versa’s AdapTR™ device outside the U.S. and in early U.S. studies.

Investors like S3 Ventures and BioStar (backers since earlier stages) continued to put money in, signaling confidence in Versa’s technology and market. The treatment targets a large underserved population (7+ million Americans with valve disease) and has a clear path to regulatory approval. This round shows that specialized medtech startups can still attract double-digit millions, funding needed for FDA studies, especially with proven leadership (ex-Medtronic VP now CEO) and strong initial trial results.

Funding Details
Startup: Versa Vascular, Inc.
Investors: S3 Ventures, BioStar Capital (existing Series C backers)
Amount Raised: $15 million (Series C expansion)
Total Raised: $42 million (total Series C)
Funding Stage: Series C (expansion)
Funding Date: Aug 11, 2026
Headquarters: Santa Cruz, California, USA
Sector: Medical Devices / Structural Heart (Cardiology)

What Today’s Funding Activity Reveals

Several clear patterns emerge. First, “vertical AI” and hard tech are hot. We’re not seeing random consumer apps getting funded, but domain-specific tech (insurance, restaurants, hospitals, aerospace) and companies blending software with physical systems. Investors are flocking to sectors where software meets the real world – whether that’s autonomous drones, lab-robotics for biology, or supply chains for restaurants. Second, geography matters less than mission-critical tech. The roundup spans the U.S., Europe, and Switzerland, but every startup is tackling a big, often global problem.

Third, there’s a cluster in defense and infrastructure. Neros’s deal and Stratasys’s additive-manufacturing grant hint at a renewed national security investment wave – likely tied to global tensions. Capital is flowing into drone and additive manufacturing tech to bolster domestic defense capabilities. Another cluster is enterprise SaaS and fintech infrastructure: inKind, Quartr, Axle and ApartmentIQ all got big checks. This suggests that investors still prioritize companies that digitize and “AI-ize” back-office functions in big industries (finance, real estate, supply chain).

Fourth, we see “sovereign technology” threads: Vertical Aerospace is UK-based (with UK government engagement), Neros is U.S. defense-focused, and multiple deals involve government-affiliated funds. It hints that VCs are aligning some bets with national industrial strategy (UK eVTOL sector, U.S. drone production).

Finally, the mix of deal sizes (from $15M to $414M) highlights that capital is concentrated among a few winners. Only a handful of companies command nine-figure raises, while most others get tens of millions. This concentration may reflect macro caution – investors are doubling down on clear winners or big visions rather than spreading small bets.

Venture Funding Table

Strategic Takeaways for Founders and Investors

• Founders should focus on real problems in large markets. The funded startups are all addressing clear, measurable pain points (e.g., debt automation in insurance, revenue for restaurants, MSK health costs). Investors want tangible impact – clever technology is table stakes. Demonstrating payback (revenue or savings) for enterprises or governments will open the funding spigot.

• Investors are prioritizing “systemic” tech with defensibility. This includes dual-use or mission-critical tech (defense drones, biotech platforms) and enterprise solutions that lock in customers (SaaS for industries like real estate or healthcare). If you’re a founder, emphasize how your product fits into an essential infrastructure rather than a one-off gadget.

• Market timing signals caution. Despite big rounds, the concentration of capital into a few deals suggests VCs are selective. Noise sectors (consumer apps, crypto) are quiet. This is a reminder to conserve cash and demonstrate traction before scaling. For investors, the willingness to lead mega-rounds in traditional sectors suggests a continued “flight to quality” – they back proven teams and markets.

• Be prepared for strategic partnerships. Many deals involved corporate VCs or government-linked funds (Citi in inKind, ASTF in Neros, Yorkville in Vertical, Citi/Mudrick). Strategic investors bring not just cash but domain expertise and distribution. Startups should align product development with such partners’ interests.

• Expect AI to be a tool, not the entire pitch. Notice that even “AI startups” here (Axle, Aureka, Quartr, Flagler) are embedded in a specific industry narrative (insurance workflows, drug R&D, financial data, health ops). Selling a general “AI platform” won’t fly – weave it into a big industry story.

• Pricing power and defensibility matter. Companies with potential recurring revenue (SaaS licenses, platform fees) are favorites. For founders, ensure your business model has scale and stickiness. For investors, look for companies with high retention and network effects (inKind’s restaurant network, Quartr’s data network, inKind’s selection of restaurant partners).

• Watch out for commoditization risks. Some AI tasks (like data analysis) are getting cheaper, so value now lies in integration and domain knowledge. Founders should focus on proprietary data or complex workflows (e.g., actual drone hardware, lab experiments, clinical results). Investors should prefer startups with unique data or regulatory barriers.

Conclusion

Today’s funding roundup underscores a clear signal: venture dollars are flowing into startups that combine cutting-edge tech with real-world heft. From $250M for drone factories to $15M for heart devices, the emphasis is on deep tech and vertical AI – not consumer buzz apps. The themes we see – defense and aerospace tech surging, healthcare and biotech booming, finance and infrastructure startups maturing – suggest a startup ecosystem that’s shifting toward specialization.

For founders, this means the bar is high: one needs a credible play in a large industry with defensible tech to capture attention. For investors, the takeaway is similar: bet on companies solving fundamental problems at scale, even if it requires long timelines. The startup world seems to be entering a mode where “serious tech” and “industrial AI” are the winning hand. As markets look ahead, expect more capital to cluster around these core themes. The big insight is that, at least today, venture capital is rewarding utility and strategic significance – and those who deliver it will shape the next chapter of innovation.